Specify a stock or a cryptocurrency in the search bar to get a summary
NextCell Pharma AB
NXTCLNextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden. Address: Karolinska Institutet Science Park, Huddinge, Sweden, 141 57
Analytics
WallStreet Target Price
–P/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures NXTCL
Dividend Analytics NXTCL
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History NXTCL
Stock Valuation NXTCL
Financials NXTCL
Results | 2019 | Dynamics |